Molecular Partners AG
MOLN
Price:
$5.2851
Market Cap:
$193.63M
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in P...[Read more]
Industry
Biotechnology
IPO Date
2021-06-16
Stock Exchange
NASDAQ
Ticker
MOLN
PE Ratio
[-2.47]
ROE
[-39.16%]
Current Ratio
[14.33]
Dividend Yield
[0%]
Enterprise Value
[130.63M]
Dividend History
The ROE as of November 2024 (TTM) for Molecular Partners AG (MOLN) is -39.16%
According to Molecular Partners AG’s latest financial reports and current stock price. The company's current ROE is -39.16%. This represents a change of 297.11% compared to the average of -9.86% of the last 4 quarters.
Molecular Partners AG (MOLN) Historical ROE (quarterly & annually)
How has MOLN ROE performed in the past?
The mean historical ROE of Molecular Partners AG over the last ten years is -24.75%. The current -39.16% ROE has changed 58.20% with respect to the historical average. Over the past ten years (40 quarters), MOLN's ROE was at its highest in in the March 2022 quarter at 57.89%. The ROE was at its lowest in in the September 2020 quarter at -61.37%.
Average
-24.75%
Median
-28.46%
Minimum
-67.03%
Maximum
50.11%
Molecular Partners AG (MOLN) ROE by Quarter and Year
Discovering the peaks and valleys of Molecular Partners AG ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 13.88%
Maximum Annual ROE = 50.11%
Minimum Annual Increase = -184.30%
Minimum Annual ROE = -67.03%
| Year | ROE | Change |
|---|---|---|
| 2023 | -35.13% | -170.10% |
| 2022 | 50.11% | -184.30% |
| 2021 | -59.45% | 1.56% |
| 2020 | -58.54% | -12.67% |
| 2019 | -67.03% | 65.97% |
| 2018 | -40.39% | 85.38% |
| 2017 | -21.79% | 58.95% |
| 2016 | -13.71% | 13.88% |
| 2015 | -0.10% | -93.62% |
| 2014 | -1.54% | -110.40% |
Molecular Partners AG (MOLN) Average ROE
How has MOLN ROE performed in the past?
The current ROE of Molecular Partners AG (MOLN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-14.82%
5-year avg
-34.01%
10-year avg
-24.75%
Molecular Partners AG (MOLN) ROE vs. Peers
How is MOLN’s ROE compared to its peers?
Molecular Partners AG’s ROE is greater than Mineralys Therapeutics, Inc. (-55.92%), greater than AN2 Therapeutics, Inc. (-57.63%), greater than Pharvaris N.V. (-38.27%), greater than PepGen Inc. (-60.17%), greater than MediciNova, Inc. (-20.70%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), less than Champions Oncology, Inc. (323.52%), greater than Cyteir Therapeutics, Inc. (-9.44%), greater than Rezolute, Inc. (-69.83%), greater than HCW Biologics Inc. (-2516.87%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Rallybio Corporation (-77.39%), less than Opthea Limited (360.15%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), less than Entrada Therapeutics, Inc. (16.11%), greater than Vigil Neuroscience, Inc. (-83.89%),
| Company | ROE | Market cap |
|---|---|---|
| -55.92% | $621.09M | |
| -57.63% | $39.99M | |
| -38.27% | $1.20B | |
| -60.17% | $143.75M | |
| -20.70% | $104.47M | |
| -184.40% | $37.86M | |
| 323.52% | $61.85M | |
| -9.44% | $108.71M | |
| -69.83% | $284.50M | |
| -2516.87% | $29.12M | |
| -47.03% | $342.68M | |
| -24.20% | $83.31M | |
| -26.83% | $3.05B | |
| -77.39% | $42.32M | |
| 360.15% | $486.27M | |
| -62.68% | $521.60M | |
| 16.11% | $703.50M | |
| -83.89% | $130.41M |
Build a custom stock screener for Molecular Partners AG (MOLN) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Molecular Partners AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Molecular Partners AG (MOLN) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Molecular Partners AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Molecular Partners AG's ROE?
How is the ROE calculated for Molecular Partners AG (MOLN)?
What is the highest ROE for Molecular Partners AG (MOLN)?
What is the 3-year average ROE for Molecular Partners AG (MOLN)?
What is the 5-year average ROE for Molecular Partners AG (MOLN)?
How does the current ROE for Molecular Partners AG (MOLN) compare to its historical average?